271 related articles for article (PubMed ID: 25827155)
21. NK1 antagonists attenuate tau phosphorylation after blast and repeated concussive injury.
Corrigan F; Cernak I; McAteer K; Hellewell SC; Rosenfeld JV; Turner RJ; Vink R
Sci Rep; 2021 Apr; 11(1):8861. PubMed ID: 33893374
[TBL] [Abstract][Full Text] [Related]
22. Substance P mediates inflammatory oedema in acute pancreatitis via activation of the neurokinin-1 receptor in rats and mice.
Grady EF; Yoshimi SK; Maa J; Valeroso D; Vartanian RK; Rahim S; Kim EH; Gerard C; Gerard N; Bunnett NW; Kirkwood KS
Br J Pharmacol; 2000 Jun; 130(3):505-12. PubMed ID: 10821777
[TBL] [Abstract][Full Text] [Related]
23. Changes in substance P and NK1 receptor immunohistochemistry following human spinal cord injury.
Leonard AV; Manavis J; Blumbergs PC; Vink R
Spinal Cord; 2014 Jan; 52(1):17-23. PubMed ID: 24216617
[TBL] [Abstract][Full Text] [Related]
24. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammation.
Nessler S; Stadelmann C; Bittner A; Schlegel K; Gronen F; Brueck W; Hemmer B; Sommer N
J Neuroimmunol; 2006 Oct; 179(1-2):1-8. PubMed ID: 16904192
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the role of substance P in the growth of brain tumors.
Harford-Wright E; Lewis KM; Vink R; Ghabriel MN
Neuroscience; 2014 Mar; 261():85-94. PubMed ID: 24374326
[TBL] [Abstract][Full Text] [Related]
26. Role of substance P in the cardiovascular system.
Mistrova E; Kruzliak P; Chottova Dvorakova M
Neuropeptides; 2016 Aug; 58():41-51. PubMed ID: 26706184
[TBL] [Abstract][Full Text] [Related]
27. Substance P does not play a critical role in neurogenic inflammation in the rat masseter muscle.
Ro JY; Zhang Y; Nies M
Brain Res; 2005 Jun; 1047(1):38-44. PubMed ID: 15885663
[TBL] [Abstract][Full Text] [Related]
28. Role of substance P in several models of bladder inflammation.
Luber-Narod J; Austin-Ritchie T; Hollins C; Menon M; Malhotra RK; Baker S; Carraway RE
Urol Res; 1997; 25(6):395-9. PubMed ID: 9443648
[TBL] [Abstract][Full Text] [Related]
29. NK1 tachykinin receptor treatment is superior to capsaicin pre-treatment in improving functional outcome following acute ischemic stroke.
Turner RJ; Vink R
Neuropeptides; 2014 Oct; 48(5):267-72. PubMed ID: 25151181
[TBL] [Abstract][Full Text] [Related]
30. Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.
Lewis KM; Turner RJ; Vink R
Int J Inflam; 2013; 2013():578480. PubMed ID: 23819099
[TBL] [Abstract][Full Text] [Related]
31. The role of tachykinins via NK1 receptors in progression of human gliomas.
Palma C; Maggi CA
Life Sci; 2000; 67(9):985-1001. PubMed ID: 10954033
[TBL] [Abstract][Full Text] [Related]
32. Pivotal role of endogenous tachykinins and the NK1 receptor in mediating leukocyte accumulation, in the absence of oedema formation, in response to TNFalpha in the cutaneous microvasculature.
Costa SK; Yshii LM; Poston RN; Muscará MN; Brain SD
J Neuroimmunol; 2006 Feb; 171(1-2):99-109. PubMed ID: 16269189
[TBL] [Abstract][Full Text] [Related]
33. Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line.
Palma C; Goso C; Manzini S
Neurosci Lett; 1994 Apr; 171(1-2):221-4. PubMed ID: 7521949
[TBL] [Abstract][Full Text] [Related]
34. Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache.
Beattie DT; Connor HE; Hagan RM
Can J Physiol Pharmacol; 1995 Jul; 73(7):871-7. PubMed ID: 8846424
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis.
Chauhan VS; Kluttz JM; Bost KL; Marriott I
J Immunol; 2011 Jun; 186(12):7255-63. PubMed ID: 21562162
[TBL] [Abstract][Full Text] [Related]
36. Substance P as a mediator of neurogenic inflammation after balloon compression induced spinal cord injury.
Leonard AV; Thornton E; Vink R
J Neurotrauma; 2013 Nov; 30(21):1812-23. PubMed ID: 23924052
[TBL] [Abstract][Full Text] [Related]
37. Esmolol activates endogenous neurokinin activity inhibiting infarction-induced arrhythmias in rats: novel mechanisms of anti-arrhythmia.
Wang LL; Han Y; Guo Z; Han SQ; Liu T
Regul Pept; 2013 Sep; 186():116-22. PubMed ID: 23994276
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke.
Turner R; Vink R
Drug News Perspect; 2007 May; 20(4):221-6. PubMed ID: 17637934
[TBL] [Abstract][Full Text] [Related]
39. Effect of the tachykinin NK1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord.
Malcangio M; Bowery NG
Br J Pharmacol; 1994 Oct; 113(2):635-41. PubMed ID: 7530576
[TBL] [Abstract][Full Text] [Related]
40. Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models.
Teodoro FC; Tronco Júnior MF; Zampronio AR; Martini AC; Rae GA; Chichorro JG
Neuropeptides; 2013 Jun; 47(3):199-206. PubMed ID: 23177733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
